Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

Petros Grivas, MD, PhD
Published: Monday, Apr 06, 2020



Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses potential combination regimens with cabazitaxel (Jevtana) in prostate cancer.

In 2010, cabazitaxel was approved for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with a docetaxel-containing regimen.

The combination of cabazitaxel and other agents could lead to improved response rates in this setting, and is currently the subject of ongoing investigation, says Grivas.

For example, the phase II CHAARTED2 trial (NCT03419234) is investigating the efficacy of abiraterone acetate (Zytiga) and antiandrogen therapy with or without cabazitaxel and prednisone in men with mCRPC who received prior therapy with docetaxel.

Results from the CHAARTED2 trial may inform the optimal treatment strategy for patients in this setting, as well as shed light on the importance of combination therapy in prostate cancer, concludes Grivas.
SELECTED
LANGUAGE


Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses potential combination regimens with cabazitaxel (Jevtana) in prostate cancer.

In 2010, cabazitaxel was approved for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with a docetaxel-containing regimen.

The combination of cabazitaxel and other agents could lead to improved response rates in this setting, and is currently the subject of ongoing investigation, says Grivas.

For example, the phase II CHAARTED2 trial (NCT03419234) is investigating the efficacy of abiraterone acetate (Zytiga) and antiandrogen therapy with or without cabazitaxel and prednisone in men with mCRPC who received prior therapy with docetaxel.

Results from the CHAARTED2 trial may inform the optimal treatment strategy for patients in this setting, as well as shed light on the importance of combination therapy in prostate cancer, concludes Grivas.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x